HC Wainwright Has Positive Outlook for SGMT FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Sagimet Biosciences to a loss of $1.31 per share from a prior loss estimate of $1.48, while maintaining a Buy rating and $29 price target.
• Sagimet reported a quarterly loss of $0.26 per share, slightly below the consensus estimate of a $0.25 loss. Analysts overall remain moderately bullish, with a consensus price target of $26.63 and nine Buy ratings versus one Hold and two Sell ratings.
• Institutional investors own 87.86% of the company, while recent insider transactions were net selling, including stock sales by the CEO and a director. Sagimet is developing denifanstat, an oral FASN inhibitor primarily being evaluated for MASH.

Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Research analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for shares of Sagimet Biosciences in a report released on Monday, October 5th. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($1.31) per share for the year, up from their previous estimate of ($1.48). HC Wainwright currently has a "Buy" rating and a $29.00 target price on the stock. The consensus estimate for Sagimet Biosciences' current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Sagimet Biosciences' Q4 2026 earnings at ($0.27) EPS, FY2027 earnings at ($1.03) EPS and FY2028 earnings at ($0.64) EPS.

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.01).

A number of other equities research analysts have also weighed in on SGMT. Citigroup restated a "market outperform" rating on shares of Sagimet Biosciences in a report on Thursday, October 1st. Cantor Fitzgerald reiterated an "overweight" rating on shares of Sagimet Biosciences in a research report on Thursday, October 1st. Canaccord Genuity Group boosted their price target on shares of Sagimet Biosciences from $49.00 to $56.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. The Goldman Sachs Group began coverage on shares of Sagimet Biosciences in a research report on Thursday, September 24th. They set a "sell" rating and a $7.00 price target for the company. Finally, Barclays upgraded Sagimet Biosciences from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $8.00 to $18.00 in a report on Wednesday, September 9th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Sagimet Biosciences presently has a consensus rating of "Moderate Buy" and an average price target of $26.63.

Sagimet Biosciences Price Performance

Shares of NASDAQ SGMT opened at $8.76 on Wednesday. The stock has a market capitalization of $544.52 million, a P/E ratio of -6.84 and a beta of 3.46. Sagimet Biosciences has a one year low of $4.50 and a one year high of $11.45. The firm's 50 day simple moving average is $9.89 and its two-hundred day simple moving average is $7.83.

Institutional Investors Weigh In On Sagimet Biosciences

Hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its stake in shares of Sagimet Biosciences by 99.4% during the first quarter. Dimensional Fund Advisors LP now owns 271,217 shares of the company's stock valued at $1,415,000 after purchasing an additional 135,178 shares in the last quarter. Seven Fleet Capital Management LP bought a new stake in shares of Sagimet Biosciences in the 2nd quarter worth approximately $3,119,000. Bank of New York Mellon Corp purchased a new stake in shares of Sagimet Biosciences in the 2nd quarter worth approximately $1,551,000. Renaissance Technologies LLC grew its stake in shares of Sagimet Biosciences by 82.6% in the 1st quarter. Renaissance Technologies LLC now owns 625,469 shares of the company's stock worth $3,268,000 after buying an additional 282,969 shares during the last quarter. Finally, AWM Investment Company Inc. bought a new position in Sagimet Biosciences during the 2nd quarter valued at approximately $618,000. Institutional investors own 87.86% of the company's stock.

Insider Buying and Selling

In related news, CEO David Happel sold 64,051 shares of the company's stock in a transaction on Monday, July 20th. The stock was sold at an average price of $7.76, for a total value of $497,035.76. Following the sale, the chief executive officer directly owned 741,570 shares of the company's stock, valued at $5,754,583.20. This represents a 7.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George Kemble sold 20,206 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $9.95, for a total value of $201,049.70. Following the completion of the transaction, the director owned 62,161 shares of the company's stock, valued at approximately $618,501.95. This trade represents a 24.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 113,646 shares of company stock valued at $920,491 over the last ninety days. Company insiders own 11.50% of the company's stock.

About Sagimet Biosciences

Sagimet Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target fatty acid synthase (FASN), an enzyme involved in the production of fatty acids. The company's research is aimed at treating diseases associated with abnormal lipid metabolism and excess fat production.

Sagimet's lead investigational product is denifanstat, an oral, selective FASN inhibitor formerly known as TVB-2640. The company is evaluating denifanstat primarily for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease that can involve inflammation, fat accumulation and fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.